Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free TRVN Stock Alerts

Trevena (TRVN) Competitors

Trevena logo
$0.01 0.00 (0.00%)
As of 09/22/2026
Compare

TRVN vs. SXTPW, BFRIW, CINGW, CLVR, and CMRAW

Should you buy Trevena stock or one of its competitors? Trevena's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Biofrontera (BFRIW), Cingulate (CINGW), Clever Leaves (CLVR), and Comera Life Sciences (CMRAW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Trevena compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and Trevena (NASDAQ:TRVN) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

60 Degrees Pharmaceuticals has higher revenue and earnings than Trevena.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.11MN/AN/AN/AN/A
Trevena$443K0.02-$40.29M-$47.04N/A

Company Net Margins Return on Equity Return on Assets
60 Degrees PharmaceuticalsN/A N/A N/A
Trevena N/A N/A -119.55%

13.6% of Trevena shares are owned by institutional investors. 2.7% of Trevena shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Trevena had 1 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 1 mentions for Trevena and 0 mentions for 60 Degrees Pharmaceuticals. Trevena's average media sentiment score of 0.37 beat 60 Degrees Pharmaceuticals' score of 0.00 indicating that Trevena is being referred to more favorably in the news media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Neutral
Trevena Neutral

Summary

Trevena beats 60 Degrees Pharmaceuticals on 4 of the 6 factors compared between the two stocks.

How does Trevena compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Trevena (NASDAQ:TRVN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Biofrontera has higher revenue and earnings than Trevena.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$46.18MN/AN/AN/AN/A
Trevena$443K0.02-$40.29M-$47.04N/A

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Trevena N/A N/A -119.55%

In the previous week, Trevena had 1 more articles in the media than Biofrontera. MarketBeat recorded 1 mentions for Trevena and 0 mentions for Biofrontera. Trevena's average media sentiment score of 0.37 beat Biofrontera's score of 0.00 indicating that Trevena is being referred to more favorably in the news media.

Company Overall Sentiment
Biofrontera Neutral
Trevena Neutral

13.6% of Trevena shares are held by institutional investors. 2.7% of Trevena shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Trevena beats Biofrontera on 4 of the 6 factors compared between the two stocks.

How does Trevena compare to Cingulate?

Trevena (NASDAQ:TRVN) and Cingulate (NASDAQ:CINGW) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

Cingulate has lower revenue, but higher earnings than Trevena.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.02-$40.29M-$47.04N/A
CingulateN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Cingulate N/A N/A N/A

In the previous week, Trevena had 1 more articles in the media than Cingulate. MarketBeat recorded 1 mentions for Trevena and 0 mentions for Cingulate. Trevena's average media sentiment score of 0.37 beat Cingulate's score of 0.00 indicating that Trevena is being referred to more favorably in the media.

Company Overall Sentiment
Trevena Neutral
Cingulate Neutral

13.6% of Trevena shares are held by institutional investors. 2.7% of Trevena shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Trevena beats Cingulate on 5 of the 6 factors compared between the two stocks.

How does Trevena compare to Clever Leaves?

Clever Leaves (NASDAQ:CLVR) and Trevena (NASDAQ:TRVN) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Trevena N/A N/A -119.55%

In the previous week, Trevena had 1 more articles in the media than Clever Leaves. MarketBeat recorded 1 mentions for Trevena and 0 mentions for Clever Leaves. Trevena's average media sentiment score of 0.37 beat Clever Leaves' score of 0.00 indicating that Trevena is being referred to more favorably in the news media.

Company Overall Sentiment
Clever Leaves Neutral
Trevena Neutral

Clever Leaves has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$9.66N/A
Trevena$443K0.02-$40.29M-$47.04N/A

6.9% of Clever Leaves shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by insiders. Comparatively, 2.7% of Trevena shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Clever Leaves has a beta of 3853.65, meaning that its stock price is 385,265% more volatile than the broader market. Comparatively, Trevena has a beta of -0.55, meaning that its stock price is 155% less volatile than the broader market.

Summary

Clever Leaves beats Trevena on 7 of the 11 factors compared between the two stocks.

How does Trevena compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRAW) and Trevena (NASDAQ:TRVN) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

In the previous week, Trevena had 1 more articles in the media than Comera Life Sciences. MarketBeat recorded 1 mentions for Trevena and 0 mentions for Comera Life Sciences. Trevena's average media sentiment score of 0.37 beat Comera Life Sciences' score of 0.00 indicating that Trevena is being referred to more favorably in the news media.

Company Overall Sentiment
Comera Life Sciences Neutral
Trevena Neutral

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Trevena N/A N/A -119.55%

13.6% of Trevena shares are owned by institutional investors. 2.7% of Trevena shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Comera Life Sciences has higher revenue and earnings than Trevena.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00MN/AN/AN/AN/A
Trevena$443K0.02-$40.29M-$47.04N/A

Summary

Trevena beats Comera Life Sciences on 4 of the 6 factors compared between the two stocks.

Get Trevena News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRVN vs. The Competition

Export
MetricTrevenaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$11K$12.41B$7.21B$13.10B
Dividend YieldN/A2.63%2.53%13.00%
P/E Ratio0.00794.80274.5825.69
Price / Sales0.02833.33639.3880.65
Price / CashN/A86.2276.3152.02
Price / Book0.0010.6210.446.32
Net Income-$40.29M$2.81B$3.49B$359.73M
7 Day PerformanceN/A0.73%0.51%1.35%
1 Month PerformanceN/A-1.67%-3.38%-3.68%
1 Year PerformanceN/A3.07%16.04%5.56%

Trevena Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRVN
Trevena
N/A$0.01
flat		N/A+12.0%$11K$443KN/A23
SXTPW
60 Degrees Pharmaceuticals
N/A$0.04
flat		N/A-22.7%$0.00$1.11MN/A2
BFRIW
Biofrontera
N/A$0.02
+1.5%		N/AN/A$0.00$46.18MN/A70
CINGW
Cingulate
N/A$0.01
-7.9%		N/A-87.6%$0.00N/AN/A20
CLVR
Clever Leaves
N/A$0.00
flat		N/AN/A$0.00$17.42MN/A560

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TRVN) was last updated on 9/23/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel